Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04353492 · ClinicalTrials.gov registry record · Phase 3
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 562
- Enrollment target
- 20
- Study locations
NCT04353492 is a Phase 3 study of Relapsing Multiple Sclerosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 562 participants, below the 2,145-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04353492, a Phase 3 study of Relapsing Multiple Sclerosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 562 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
Conditions Studied
Interventions
- BIOLOGICAL Ofatumumab
Study Locations (20)
Florida
- Memorial Healthcare System - Hollywood
- Homestead Assoc In Research Inc - Homestead
- Neurology Associates PA - Maitland
- UM Department Of Neurology - Miami
- Negroski Neurology - Sarasota
- Axiom Clinical Research of Florida - Tampa
- University Of South Florida - Tampa
- Premiere Research Institute - West Palm Beach
Georgia
- Atlanta Neuroscience Institute - Atlanta
- Georgia Neurology and Sleep Medicine Assoc - Suwanee
Ohio
- Cleveland Clinic Foundation - Cleveland
- Columbus Neuroscience - Westerville
California
- Fullerton Neuro and Headache Ctr - Fullerton
Colorado
- CU Anschutz Med Campus - Aurora
Delaware
- Christiana Care Health Services - Newark
Maryland
- Johns Hopkins Hospital - Baltimore
Nevada
- Cleveland Clinic Foundation - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 562 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2025-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04353492
The ClinicalTrials.gov registry entry for NCT04353492 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 562 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,145-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (74% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ofatumumab is the first listed.
NCT04353492 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT04353492 about?
NCT04353492 is a clinical study titled "An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab". Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
What is the current status of trial NCT04353492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 562 participants. The study started on 2020-07-14. Estimated completion is 2025-03-11.
What conditions does trial NCT04353492 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT04353492?
The interventions under investigation include: Ofatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04353492?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04353492 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.